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Summary Purpose: Tiagabine is a unique antiepileptic drug with a novel mecha-
nism of action. Whilst some limited data are available as to the peripheral blood
pharmacokinetics of tiagabine, data regarding the kinetics of tiagabine in the cen-
tral brain compartment are very limited. We therefore sought to investigate serum,
cerebrospinal ﬂuid (CSF) and frontal cortex and hippocampal extracellular ﬂuid (ECF)
kinetic inter-relationship of tiagabine in a freely moving rat model. Methods: Adult
male rats were implanted with either a jugular vein catheter and a cisterna magna
catheter for blood and CSF sampling, respectively, or a blood catheter and a micro-
dialysis probe in the hippocampus and frontal cortex (for ECF sampling). Tiagabine was
administered intraperitoneal (i.p.) at 20 or 40mg/kg and blood, CSF and ECF were col-
lected at timed intervals for themeasurement of tiagabine concentrations by high per-
formance liquid chromatography. Results: Tiagabine concentrations in blood and CSF
rose linearly and dose-dependently and time to maximum concentration (Tmax) was
15 and 29min, respectively. Mean CSF/serum tiagabine concentration ratios (range,
0.008—0.01) were much smaller than the mean free/total tiagabine concentration
ratios in serum (0.045± 0.003). Entry of tiagabine into brain ECF (frontal cortex and
hippocampus) was rapid with Tmax values of 31—46min. Distribution of tiagabine in
brain was not brain region speciﬁc with values in the frontal cortex and hippocampus
being indistinguishable. Whilst elimination from CSF was comparable to that of serum,
half-life (t1/2) values in ECF were three times longer. Conclusions: Tiagabine is asso-
ciated with linear kinetic characteristics and with rapid brain penetration. However,
CSF concentrations are not reﬂective of free non-protein-bound concentrations in
serum. The observation that tiagabine elimination from the brain is threefold slower
than that seen in blood, may explain as to the relatively long duration of action of
tiagabine.
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Introduction
Tiagabine ([R-(−)-N-(4,4-di-(3-methylthien-2-yl)-
but-3-enyl) nipecotic acid] hydrochloride) is a
unique antiepileptic drug (AED) with a novel mech-
anism of action in that it selectively and specif-
ically inhibits the uptake of -aminobutyric acid
(GABA) into astrocytes and neurones, by the trans-
porter GAT-1, and thus increases the extracellular
concentration of GABA in the brain. Tiagabine is
effective in the management of partial seizures
with or without secondary generalisation, and is
licensed for use as adjunctive therapy in patients
refractory to available ﬁrst-line AEDs.1—4
Tiagabine is effective in a variety of seizure
models including amygdala-kindled seizures,5 au-
diogenic seizures6 and convulsions associated with
status epilepticus induced in cobalt-lesioned rats by
the administration of homocysteine thiolactone.7
The latter observation raises the possibility that it
may be useful in the management of status epilep-
ticus in patients. However, from a pharmacokinetic
aspect, drugs used in the management of status
epilepticus need to be able to rapidly and efﬁ-
ciently penetrate the blood—brain barrier and to
have an elimination half-life that does not require
frequent dosing.
Whilst data on the blood pharmacokinetics of
tiagabine in man are abundant,8 such data are
scarce in the rat.9 Furthermore, data regarding
the kinetics of tiagabine in the brain are very lim-
ited indeed; one study has reported on whole brain
tiagabine concentrations at 1 h after intraperito-
nial administration of tiagabine.10 Tiagabine con-
centrations increased dose-dependently and were
higher in the dorsal cortex compared to those mea-
sured in the cerebellum. Some additional informa-
tion on the central brain kinetics of tiagabine can
be deduced indirectly via observation of central
GABA changes. Thus, tiagabine dose-dependently
increased GABA extracellular ﬂuid (ECF) concentra-
tions two- to threefold in the globus pallidus, ven-
tral pallidum and in the substantia nigra of rats.11
However, tiagabine had no effect on cerebrospinal
ﬂuid (CSF) GABA concentrations after 2 days of
tiagabine administration (50—200mg/kg/day).12 A
microdialysis study of a single patient with epilepsy,
reported an ∼50% increase in GABA ECF concentra-
tions at 1 h after a single dose of oral tiagabine in-
gestion and the increase was sustained for several
hours.13
The present study sought to ascertain the
peripheral blood pharmacokinetic and central
brain (CSF and ECF) kinetic inter-relationship of
tiagabine using a well established and validated rat
model.14—16
Methods
Animals
Male Sprague—Dawley rats weighing 250—300 g (A.
Tuck & Son Ltd., Battlesbridge, Essex, UK) were
group-housed in contiguous cages and fed ad libitum
on normal laboratory diet (SDS R and M number 1
expanded, Scientiﬁc Dietary Services, Witham, Es-
sex, UK) and water. A 12-h light—dark cycle (lights
on 06:00 h) and ambient temperature of 25 ◦C were
maintained. All the rats were allowed to acclimatise
to their new environment for at least 3 days prior
to experimentation. All animal procedures strictly
followed Home Ofﬁce regulations and were per-
formed under the Animal (Scientiﬁc Procedures) Act
1986.
Surgical procedures, blood, CSF and
microdialysis sampling
Rats were anaesthetised with 2% halothane (Merial
Animal Health Ltd., Dublin, Ireland) inhalation. Two
surgical procedures were undertaken. In the ﬁrst
group of rats, catheters were implanted in the right
jugular vein for blood sampling and in the cisterna
magna for CSF sampling as previously described.14
For the second group of rats the procedure in-
volved the implantation of a catheter in the right
jugular vein for blood sampling and a microdialy-
sis probe in both the hippocampus (from bregma
5.6mm posterior, 5mm lateral, 8.2mm ventral)
and the frontal cortex (from bregma 2.5mm ante-
rior, 1.5mm lateral, 5.5mm ventral) for monitoring
of the ECF. Stereotaxic placement of the probes
was according to the atlas of Paxinos and Watson.17
Post-surgery rats were housed singly in perspex
cages.
Two days later, when animals had fully recov-
ered, the microdialysis probes and the CSF and
blood catheters were checked for patency. Animals
with blood and CSF catheters were investigated as
follows: 20 or 40mg/kg tiagabine was administered
by intraperitoneal (i.p.) injection. Blood (200l)
and CSF (20l) were sampled via the implanted
catheters at timed intervals over a 7-h period (15,
30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 390
and 420min). In order to prevent the development
of hypovolemia, an equivalent volume of hep-
arinized saline was administered after each blood
sampling. Blood samples were collected in 0.5ml
polyethylene tubes (Treff AG, Switzerland), vortex
mixed and centrifuged at 10,000 rpm for 5min (Ab-
bott micro-centrifuge, Abbott Diagnostics, Maid-
enhead, UK). Supernatant serum and CSF were
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stored frozen (−70 ◦C) until analysis for tiagabine
content.
Animals with blood catheters and microdialy-
sis probes were investigated as follows: Artiﬁcial
CSF (CSF composition (in mM): NaCl 125, KCl 2.5,
MgCl2 1.18 and CaCl2·1.26) was perfused through
the probes at 2l/min. A baseline sample of blood
(200l) and three baseline dialysate samples (20l)
were taken before drug administration. The rats
were then injected i.p. with 40mg/kg tiagabine
and venous blood samples (200l) were withdrawn
at 10, 20, 30, 40, 50, 60, 75, 90, 105 and 120min.
Dialysate samples (20l) were collected at 10-min
intervals for the ﬁrst 60min and at 15-min inter-
vals for the subsequent 60-min period and sampling
time was corrected for dead-space volume time.
Blood and microdialysate samples were collected
in 0.5ml polyethylene tubes (Treff AG). Blood
samples were prepared as described above and su-
pernatant serum and microdialysate were stored
frozen (−70 ◦C) until analysis for tiagabine content.
Microdialysis probe construction and
in vitro recovery
Concentric microdialysis probes with ﬁltral 12
(Hospal, Rugby, UK) dialysis membrane (4mm long,
200m diameter) and internal vitreous silica tub-
ing (SGE, Milton Keynes, UK) were prepared as
previously described. In vitro probe recovery was
determined by placing each microdialysis probe
into a beaker containing a solution of 200 nmol/l
tiagabine, constituted in artiﬁcial CSF, and then
perfusing with artiﬁcial CSF at 37 ◦C with a ﬂow
rate of 2l/min. Samples (40l) were collected
every 20min for 120min and stored at −70 ◦C until
analysis for tiagabine content.
Measurement of tiagabine concentration
Tiagabine concentrations in serum, CSF and
microdialysates were measured by high perfor-
mance liquid chromatography (HPLC). The HPLC
system comprised: a Gilson 307 pump, a Gilson 234
autoinjector, ESA coulochem electrochemical de-
tector and an analytical cell (model 5011). A Hyper-
sil BDS-C18, 3m, 125mm× 3mm column (Hewlett
Packard, Stockport, Cheshire, UK) and LiChro-
sphere select B 4× 4 (5m) pre-column (Hewlett
Packard) were used. Chromatograms were collated
using Unipoint System Software (Version 1.71).
The lower limit of quantiﬁcation for tiagabine was
0.5 nmol/l (CV, 6%). The lower limit of detection
was 0.1 nmol/l. The procedure used for the de-
termination of the free non-protein-bound serum
tiagabine concentration was the same as for to-
tal tiagabine concentrations except that samples
were ﬁrst ﬁltered through an Amicon Centrifree
Micropartition System (Amicon, Stonehouse, UK)
using a Sigma 2K15 centrifuge with a temperature
setting of 25 ◦C.
Kinetic and statistical analysis
Pharmacokinetic parameters were computed (Mi-
crosoft Excel) based on a one-compartment model
for CSF and microdialysate and a two-compartment
model for blood with ﬁrst order elimination. The
following pharmacokinetic parameters were deter-
mined: time to maximal concentration (Tmax), max-
imal concentration (Cmax), terminal elimination
half-life (t1/2) and area under the concentration
versus time curve (AUC). The AUC was calculated
by linear trapezoid summation and extrapolation to
inﬁnite time as appropriate. The Ke was estimated
by least-square regression analysis of the termi-
nal log-linear portion of the plasma concentration
versus time proﬁle. The (t1/2) was calculated by
dividing the natural log of 2 by Ke. Cmax and Tmax
were read directly from the concentration versus
time curves.
Non-parametric Mann—Whitney tests were used
to ascertain signiﬁcance and a P value of 0.05 was
considered statistically signiﬁcant.
Results
Blood pharmacokinetics
Tiagabine pharmacokinetic parameters in serum
after 20 and 40mg/kg tiagabine administration are
shown in Table 1. Tiagabine concentrations rose
dose-dependently and Cmax values were achieved at
the time of ﬁrst sampling (15min post-dose). Con-
centrations subsequently declined rapidly and the
decline was exponential (Fig. 1). Both Cmax and AUC
values increased linearly and dose-dependently.
Tiagabine t1/2 values were 55± 2.3min and
50± 2.6min after 20 and 40mg/kg administration,
respectively, and were not statistically different
(P>0.05, Mann—Whitney test). At 240min and at
subsequent time points tiagabine concentrations
were just quantiﬁable and were of the order of
150 nmol/l.
The free non-protein-bound tiagabine concentra-
tion was determined in serum. At 15min post-dose
(the time of ﬁrst sample), the tiagabine free frac-
tionwas 1.4%. However, subsequent samples (n = 8)
showed a larger free fraction value (4.5± 0.3%) and
were both time and concentration independent.
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Table 1 Pharmacokinetic parameters of tiagabine in serum, CSF and brain ECF after tiagabine administration at
20 and 40mg/kg (n = 5—7).
Tmax (min) Cmax (nmol/l) AUC (nmol h/l) t1/2 (min)
Serum
Tiagabine (20mg/kg) 15 ± 0 14905 ± 1733 9439 ± 909 55 ± 2.3
Tiagabine (40mg/kg) 16 ± 0.3 27754 ± 2000 25147 ± 3491 50 ± 2.6
CSF
Tiagabine (20mg/kg) 28 ± 0.7 49 ± 6.7 51 ± 7.6 40 ± 2.6
Tiagabine (40mg/kg) 32 ± 0.9 95 ± 5.4 138 ± 13 64 ± 2.7
ECF
Tiagabine (40mg/kg)
Frontal cortex 41 ± 5 35 ± 1 154 ± 25 174 ± 32
Hippocampus 34 ± 3 38 ± 2 134 ± 10 133 ± 9
All values are mean± S.E.M. Tmax: time to maximal concentration; Cmax: maximal concentration; AUC: area under
the concentration vs. time curve; t1/2: terminal elimination half-life; CSF: cerebrospinal ﬂuid; ECF: extracellular
ﬂuid.
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Figure 1 Tiagabine (TGB) concentration vs. time proﬁles in serum after 20mg/kg () and 40mg/kg () TGB
administration. Values are mean± S.E.M. (n = 5—7).
Neuropharmacokinetics
CSF
The kinetic constants after 20 and 40mg/kg
tiagabine administration in CSF are shown in
Table 1. After drug administration, tiagabine
rapidly and readily penetrated into the CSF com-
partment and tiagabine was detectable in CSF at
the time of ﬁrst sampling (15min; Fig. 2). Mean
Tmax values varied between 28 and 32min and were
dose-independent. However, compared to serum,
CSF Tmax values were double the value (30min ver-
sus 15min). Cmax and AUC values increased linearly
and dose-dependently. In contrast to serum CSF
t1/2 values were signiﬁcantly longer after 40mg/kg
tiagabine administration (64± 2.7min) compared
to when 20mg/kg tiagabine was administered
(40± 2.6min; P < 0.01, Mann—Whitney test).
Fig. 3 shows the tiagabine concentration ratio of
CSF/serum over time after 40mg/kg tiagabine ad-
ministration. There was a tendency towards equi-
libration (as determined by a constant CSF/serum
tiagabine concentration ratio) by 30min post-
tiagabine administration. Rapid equilibration was
also observed after administration of 20mg/kg
tiagabine (data not shown). Mean CSF/serum ra-
tios were 0.008± 0.0006 after 20mg/kg tiagabine
administration and 0.01± 0.0009 after 40mg/kg
tiagabine administration. These values are not sta-
tistically different (P>0.05, Mann—Whitney test).
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Figure 2 Tiagabine (TGB) concentration vs. time proﬁles in CSF after 20mg/kg () and 40mg/kg () TGB adminis-
tration. Values are mean± S.E.M. (n = 5—7).
Extracellular ﬂuid kinetics
The mean± S.E.M in vitro recovery for tiagabine
for all the microdialysis probes was 10± 0.3% at a
dialysate ﬂow rate of 2l/min. The artiﬁcial CSF
solution used contained 200 nmol/l tiagabine and
these recovery data were used to adjust the in vivo
ECF concentration data.
The pharmacokinetic parameters of tiagabine in
brain ECF frontal cortex and hippocampus after
40mg/kg tiagabine administration are shown in
Table 1. The corresponding tiagabine concentration
versus time proﬁles are shown in Fig. 4. After drug
administration, blood—brain barrier penetration
was rapid and tiagabine was detectable at the time
of ﬁrst sampling (10min post-dose). Mean Tmax
values for frontal cortex and hippocampus were
41± 5min and 34± 3min, respectively. AUC values
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Figure 3 CSF/serum tiagabine (TGB) concentration ratios vs. time after 40mg/kg TGB administration. Values are
mean± S.E.M. (n = 5).
were comparable for frontal cortex and hippocam-
pus (154± 25 nmol h/l versus 134± 10 nmol h/l,
respectively). Overall, there were no statistically
signiﬁcant difference in tiagabine kinetic parame-
ters between brain frontal cortex and hippocam-
pus (P>0.05, Mann—Whitney test). However, the
half-life values in ECF frontal cortex and hippocam-
pus were signiﬁcantly longer (up to three times)
than that seen in the CSF and in blood.
Fig. 5 shows the tiagabine concentration ratio
of ECF/serum for frontal cortex and hippocampus
over time after 40mg/kg tiagabine administra-
tion. In contrast to CSF, there was no tendency
towards equilibration (as determined by a rising
ECF/serum tiagabine concentration ratio) dur-
ing the study period of up to 120min. However,
the mean ECF/serum ratios for frontal cortex
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Figure 4 Tiagabine (TGB) concentration vs. time proﬁles in frontal cortex () and hippocampal () ECF after
40mg/kg TGB administration. Values are mean± S.E.M. (n = 5—7).
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Figure 5 ECF/serum tiagabine (TGB) concentration ratios vs. time proﬁles in frontal cortex () and hippocampal
() after 40mg/kg TGB administration. Values are mean± S.E.M. (n = 5—7).
and hippocampus were indistinguishable (P>0.05,
Mann—Whitney test).
Discussion
This is the ﬁrst study to investigate the temporal
pharmacokinetic inter-relationship of tiagabine in
blood, CSF and brain ECF. The major ﬁndings of this
study are: (1) the pharmacokinetics of tiagabine in
serum are linear and dose-dependent; (2) tiagabine
is substantially protein bound (95%) in serum; (3)
the elimination of tiagabine from serum is rapid
(t1/2 values, 50—55min) and independent of dose;
(4) tiagabine rapidly and readily penetrated the
blood—brain barrier and was detectable within min-
utes in both CSF and brain ECF; (5) although the CSF
pharmacokinetics of tiagabine paralleled that seen
in serum, CSF concentrations did not reﬂect free
drug concentrations in serum; (6) whilst tiagabine
t1/2 values were comparable in CSF and serum, val-
ues were three times larger in frontal cortex and
hippocampal ECF; (7) tiagabine distribution in brain
frontal cortex and hippocampal ECF were indistin-
guishable.
Although there is a lack of published studies
describing the kinetics of tiagabine in the rat,
the sparse data reported by Suzdak and Jansen9
are generally in agreement with those described
in the present report. After oral ingestion of an
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unspeciﬁed tiagabine dose, tiagabine Tmax values
were ∼30min;9 slightly longer, as might be ex-
pected, compared to after i.p. administration in
the present study (Table 1). Tiagabine serum pro-
tein binding was also comparable (92—93% versus
95—96%, this study). That in the present study ECF
tiagabine t1/2 values were three times longer than
that observed in the blood compartment (Table 1),
corroborates the indirect data presented by Suz-
dak and Jansen.9 It was noted that although after
[14C]tiagabine administration (dose and route of
administration were not reported) the decrease
in tissue concentrations of [14C]tiagabine (liver,
kidney and lung) followed the decrease in serum
concentrations, the brain/plasma ratio remained
constant. This was interpreted by the authors as in-
dicating a slower elimination of tiagabine from the
brain or that equilibration between serum and brain
is slow. Indeed, the data presented in the present
study would suggest that both these processes
might pertain (Table 1 and Fig. 5). Furthermore,
the CSF t1/2 values reported in the present study
were signiﬁcantly larger at the higher tiagabine
dose (40mg/kg; 64± 2.7min) when compared
to values obtained at the lower dose (20mg/kg;
40± 2.6min). These data corroborate the obser-
vation that elimination of tiagabine from the brain
was dose-dependent.9 Lastly, the observation that
the distribution of tiagabine in the frontal cortex
and hippocampus is similar is in agreement with the
in vitro tissue binding studies with [3H]tiagabine.18
The rate of penetration of drugs, including AEDs,
into CSF and brain is considered to be determined
essentially by three physiochemical characteristics,
namely degree of ionisation, lipid solubility and de-
gree of serum protein binding. In relation to AEDs,
lipid solubility appears to be the major determinant
of rate of entry into the CSF compartment.19 Be-
cause tiagabine has high lipid solubility it would be
expected to gain rapid entry into the brain and in-
deed this was the case as tiagabine was detectable
in both CSF and frontal cortex and hippocampal ECF
at the time of ﬁrst sampling (10—15min post-dose).
Furthermore, the rate of entry into the CSF was not
dose-dependent, as there was no difference in Tmax
values after different tiagabine dose administration
(20 and 40mg/kg). Thus, tiagabine transportation
across the blood—CSF barrier in the choroid plexus
was not rate-limiting at the concentration ranges
achieved. This characteristic may very well apply to
transportation of tiagabine across the blood—brain
barrier but since the kinetics of tiagabine in frontal
cortex and hippocampal ECF were determined af-
ter only one tiagabine dose (40mg/kg) this can-
not be deﬁnitively conclude from the present
data.
Free (non-protein-bound) drug concentrations
in serum are often used as a reﬂection of CNS
drug concentrations. In the present study, mean
CSF/serum tiagabine concentration ratios (range,
0.008—0.01) are much smaller than the mean
free/total tiagabine concentration ratios in serum
(0.045± 0.003). These data suggest that free
tiagabine serum concentrations do not accurately
reﬂect CSF tiagabine concentrations. This is in con-
trast to other AEDs (e.g. carbamazepine, pheny-
toin, primidone, phenobarbitone and lamotrigine)
studied in this animal model where CSF concentra-
tions do reﬂect free drug concentrations in serum
and emphasises the importance of studying the
central neuropharmacokinetics of a drug at the site
of drug action.14,16,20,21
That tiagabine elimination from the brain is much
slower than that that occurs in serum could be of
signiﬁcant clinical importance since it would sug-
gest that the pharmacological effect of tiagabine is
much longer than that that would be suggested by
its blood pharmacokinetic proﬁle. Thus, the short
tiagabine t1/2 in serum, which is generally per-
ceived as a disadvantage for the clinical therapeu-
tics of tiagabine,16 may actually not be as relevant
if indeed the data observed in the present study
could be extrapolated to man. A further consid-
eration in relation to the difference between the
central and peripheral kinetics of tiagabine would
be that if the dosing strategy for tiagabine is based
on its serum kinetics, tiagabine would accumulate
in the brain. Thus, if non-convulsive status epilep-
ticus, that has been reported in patients treated
with tiagabine,22—24 is the consequence of GABAer-
gic hyperfunction, as has been suggested,25 then it
could be the consequence of tiagabine accumula-
tion in the brain.
The tiagabine doses used in the present study (20
and 40mg/kg) are higher than the ED50 for tiagabine
in animal seizure models26 or indeed doses that
are used clinically.4 Because tiagabine is highly pro-
tein bound (95—96%), only a very small proportion
(4—5%) of the tiagabine concentration achieved in
blood passes the blood—brain barrier to enter the
CSF and ECF compartments. Consequently, dose se-
lection was based on the rationale and the need
to achieve quantiﬁable tiagabine concentrations in
CSF and ECF. That the doses used in the present
study do not impede on the value of the data col-
lected, is evidenced by the fact that the overall
conclusions reached are similar to those described
by Suzdak and Jansen.9
Finally, the regional distribution of tiagabine in
the brain needs some comment. The present study
clearly shows that the distribution of tiagabine
in frontal cortex and hippocampal ECF is almost
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identical and the data corroborate data from in
vitro tissue binding studies with [3H]tiagabine.18
GABA transporters (designated GAT-1, GAT-2,
GAT-3 and BGT-1 according to their pharmacolog-
ical sensitivity)27 have a differential anatomical
distribution throughout the nervous system.28,29
As GAT-1 is primarily located in the cerebral cor-
tex and hippocampus and as tiagabine (through its
speciﬁcity for GAT-1) is equally distributed in these
brain regions, it would be expected the pharmaco-
logical action of tiagabine would be brain region
speciﬁc.
In conclusion, this study has shown that tiagabine
has linear peripheral and central kinetics and with
rapid brain and CSF penetration although CSF con-
centrations do not reﬂect free drug concentrations
in serum. Its distribution in brain cerebral cortex
and hippocampus would suggest it is not region spe-
ciﬁc and its elimination from the brain greatly out-
lasts that seen in blood.
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